In the patient population diagnosed with inflammatory bowel disease, the prevalence of ANAs is approximately 14%, while seroconversion occurs in approximately 28% of individuals undergoing immunosuppressive anti-TNF therapy [74]. Here, TNF is linked to inflammatory bowel disease.